de Castro G Jr, Kudaba I, Wu YL, Lopes G, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score >/= 1% in the KEYNOTE-042 Study. J Clin Oncol 2022 Oct 28:JCO2102885. doi: 10.1200/JCO.21.02885.
PMID: 36306479